Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
Talha Bin Emran1,2, Asif Shahriar3, Aar Rafi Mahmud4
1Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.
Abstract:
Cancer is one of the leading causes of death worldwide. Several treatments are available for cancer treatment, but many treatment methods are ineffective against multidrug-resistant cancer. Multidrug resistance (MDR) represents a major obstacle to effective therapeutic interventions against cancer. This review describes the known MDR mechanisms in cancer cells and discusses ongoing laboratory approaches and novel therapeutic strategies that aim to inhibit, circumvent, or reverse MDR development in various cancer types. In this review, we discuss both intrinsic and acquired drug resistance, in addition to highlighting hypoxia- and autophagy-mediated drug resistance mechanisms. Several factors, including individual genetic differences, such as mutations, altered epigenetics, enhanced drug efflux, cell death inhibition, and various other molecular and cellular mechanisms, are responsible for the development of resistance against anticancer agents. Drug resistance can also depend on cellular autophagic and hypoxic status. The expression of drug-resistant genes and the regulatory mechanisms that determine drug resistance are also discussed. Methods to circumvent MDR, including immunoprevention, the use of microparticles and nanomedicine might result in better strategies for fighting cancer.
Insights
Multidrug resistance (MDR) in cancer hinders effective treatment. This review explores MDR mechanisms and novel strategies like nanomedicine to overcome this challenge in cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer remains a leading global cause of death.
- Multidrug resistance (MDR) significantly impedes effective cancer treatment.
- Understanding MDR is crucial for developing better therapeutic strategies.
Purpose of the Study:
- To review known mechanisms of multidrug resistance in cancer cells.
- To discuss current laboratory approaches and novel therapeutic strategies to combat MDR.
- To highlight intrinsic, acquired, hypoxia-, and autophagy-mediated drug resistance.
Main Methods:
- Literature review of existing research on cancer multidrug resistance.
- Analysis of molecular and cellular mechanisms contributing to drug resistance.
- Exploration of emerging therapeutic strategies and technologies.
Main Results:
- MDR arises from genetic factors, epigenetics, drug efflux, and cell death inhibition.
- Hypoxia and autophagy play significant roles in mediating drug resistance.
- Expression of drug-resistant genes and regulatory mechanisms are key factors.
Conclusions:
- Novel strategies like immunoprevention, microparticles, and nanomedicine show promise in overcoming MDR.
- Targeting MDR mechanisms is essential for improving cancer treatment outcomes.
- Further research into these strategies could lead to more effective cancer therapies.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...


